latest news releases from the newsroom
LifePoint, Inc. Releases Financial Results for the First Quarter Ended June 30, 2004
ONTARIO, Calif., Aug. 12, 2004 (PRIMEZONE) -- LifePoint, Inc. (AMEX:LFP), a leader in non-invasive drug diagnostic technologies and solutions, today announced financial results for the first quarter ended June 30, 2004. Net loss for the first quarter ended June 30, 2004 was $2.2 million, or $0.04 per share, compared to a net loss of $2.0 million, or $0.05 per share, for the first quarter ended June 30, 2003. Net loss applicable to common stockholders for the first quarter ended June 30, 2004 was $2.3 million, or $0.04 per share, compared to a net loss applicable to common stockholders of $2.4 million, or $0.06 per share for the first quarter ended June 30, 2003.
Discovery Laboratories, Inc.
Surfaxin Receives Orphan Drug Designation from European Commission
DOYLESTOWN, Pa., Aug. 12, 2004 (PRIMEZONE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that the Commission of the European Communities has designated Surfaxin(r) as an Orphan Medicinal Product. This designation is for the prevention of Respiratory Distress Syndrome (RDS) in premature neonates of less than 32 weeks of gestational age and for the treatment of RDS in premature neonates of less than 37 weeks of gestational age. Designation was granted following the positive opinion given by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Evaluation Agency (EMEA) in which the COMP concluded that although satisfactory methods of prevention and treatment of RDS have been authorized in Europe, justifications have been provided that Surfaxin may be of significant benefit to those at risk of developing or affected by the condition.
Stratus Services Group, Inc.
Stratus Services Group, Inc. Announces Completion of Final Closing on Unit Offering
MANALAPAN, N.J., Aug. 12, 2004 (PRIMEZONE) -- Stratus Services Group, Inc., the SMARTSolutions(tm) Company (OTCBB:SSVG), announced today that it completed the final closing of its offering of up to a maximum of 12,500,000 units, with each unit consisting of one share of the Company's common stock and one common stock purchase warrant, after giving effect to its reverse split. The offering price was $.80 per unit. The exercise price of the warrants, each of which entitles the holder to purchase one share of common stock, is $.76 per share.
Harsco Corporation Successfully Renews Revolving Credit Facility
HARRISBURG, Pa., Aug. 12, 2004 (PRIMEZONE) -- Worldwide industrial services and products company Harsco Corporation (NYSE:HSC) announced today that it has successfully renewed its revolving credit facility to a new $350 million, three-year term. The facility was arranged through a syndicate of banks led by JPMorgan Chase, and serves as backup to Harsco's investment-grade commercial paper programs, rated A-2 by Standard & Poor's, P-2 by Moody's and F2 by Fitch IBCA. Harsco Senior Vice President, Chief Financial Officer and Treasurer Salvatore D. Fazzolari said the new facility, which was substantially oversubscribed, demonstrates the continued confidence of the lending community in Harsco's financial strength and long-term business outlook.